Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment

International Journal of Cancer

Volumn 76, Issue 5, 1998, Pages 729-737

  Jetté, Lucie ^a,b   Murphy, Gérard F ^c   Béliveau, Richard ^a,b  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; IODINE 125; PRAZOSIN; VERAPAMIL; VINBLASTINE;

ANIMAL TISSUE; ARTICLE; BRAIN CAPILLARY; BRUSH BORDER; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AZIDES; BLOTTING, WESTERN; BRAIN; CALCIUM CHANNEL BLOCKERS; CAPILLARIES; CYCLOSPORINE; CYCLOSPORINS; DRUG INTERACTIONS; FLUORESCENT DYES; INJECTIONS, SUBCUTANEOUS; IODINE RADIOISOTOPES; KIDNEY; LIVER; MALE; MICROVILLI; P-GLYCOPROTEIN; PHOTOAFFINITY LABELS; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; RHODAMINES; VERAPAMIL; VINBLASTINE;

EID: 0031780610     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980529)76:5<729::AID-IJC19>3.0.CO;2-Z     Document Type: Article

References (24)

1. ARCHINALMATTHEIS, A., RZEPKA, R.W., WATANABE, T., KOKUBU, N., ITOH, Y., COMBATES, N.J., BAIR, K.W. and COHEN, D., Analysis of the interactions of SDZ PSC 833 ([3'-keto-bmt1]-[val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 7, 603-610 (1995).
2. BOESCH, D., GAVÉRIAUX, C., JACHEZ, B., POURTIER-MANZANEDO, A., BOLLINGER, P. and LOOR, F., In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233 (1991a).
3. BOESCH, D. and LOOR, F., Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anti-Cancer Drugs, 5, 229-238 (1994).
4. BOESCH, D., MULLER, K., POURTIER-MANZANEDO, A. and LOOR, F., Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196, 26-32 (1991b).
5. BOHME, M., BUCHLER, M., MULLER, M. and KEPPLER, D., Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett., 333, 193-196 (1993).
6. BOOTE, D.J., DENNIS, I.F., TWENTYMAN, P.R., OSBORNE, R.J., LABURTE, C., HENSEL, S., SMYTH, J.F., BRAMPTON, M.H. and BLEEHEN, N.M., Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. clin. Oncol., 14, 610-618 (1996).
7. BUSCHMAN, E. and GROS, P., The inability of the mouse mdr2 gene to confer multidrug-resistance is linked to reduced drug-binding to the protein. Cancer Res., 54, 4892-4898 (1994).
8. CORDON-CARDO, C., O'BRIEN, J.P., BOCCIA, J., CASALS, D., BERTINO, J.R. and MELAMED, M.R., Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 38, 1277-1287 (1990).
9. CROOP, J.M., RAYMOND, M., HABER, D., DEVAULT, A., ARCECI, R.J., GROS, P. and HOUSMAN, D., The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. cell. Biol., 9, 1346-1350 (1989).
10. DIDIER, A.D. and LOOR, F., Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int. J. Cancer, 63, 263-267 (1995).
11. FOJO, A.T., UEDA, K., SLAMON, D.J., POPLACK, D.G., GOTTESMAN, M.M. and PASTAN, I., Expression of a multidrug-resistance gene in human tumors and tissues. Proc. nat. Acad. Sci. (Wash.), 84, 265-269 (1987).
12. GAVÉRIAUX, C., BOESCH, D., JACHEZ, B., BOLLINGER, P., PAYNE, T. and LOOR, F., SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J. cell. Pharmacol., 2, 225-234 (1991).
13. GONZALEZ, O., COLOMBO, T., DE FUSCO, M., IMPERATORI, L., ZUCCHETTI, M. and D'INCALCI, M., Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol., 36, 335-340 (1995).
14. GOTTESMAN, M.M. and PASTAN, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem., 62, 385-427 (1993).
15. HU, X.F., SLATER, A., WALL, D.M., PARKIN, J.D., KANTHARIDIS, P. and ZALCBERG, J.R., Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin. Cancer Res., 2, 713-720 (1996).
16. HWANG, M., AHN, C.-H., PINE, P.S., YIN, J.-J., HRYCYNA, C.A., LICHT, T. and ASZALOS, A., Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int. J. Cancer, 65, 389-397 (1996).
17. JACHEZ, B., CIANFRIGLIA, M. and LOOR, F., Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents. Anti-Cancer Drugs, 5, 655-665 (1994).
18. JETTÉ, L., BEAULIEU, E., LECLERC, J.-M. and BÉLIVEAU, R., Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Amer. J. Physiol., 270, F756-F765 (1996).
19. JETTÉ, L., MURPHY, G.F., LECLERC, J.-M. and BÉLIVEAU, R., Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol., 50, 1701-1709 (1995a).
20. JETTÉ, L., POULIOT, J.-F., MURPHY, G.F. and BÉLIVEAU, R., Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein. Biochem. J., 305, 761-766 (1995b).
21. LEMAIRE, M., BRUELISAUER, A., GUNTZ, P. and SATO, H., Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing Cyclosporin, in rats. Cancer Chemother. Pharmacol., 38, 481-486 (1996).
22. LUM, B.L., GOSLAND, M.P., KAUBISCH, S. and SIKIC, B.I., Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy, 13, 88-109 (1993).
23. SAEKI, T., UEDA, K., TANIGAWARA, Y., HOORI, R. and KOMANO, T., Human P-glycoprotein transports cyclosporin A and FK506. J. biol. Chem., 268, 6077-6080 (1993).
24. SPEEG, K.V. and MALDONADO, A.L., Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34, 133-136 (1994).